Skip to main content
. 2022 Jul 29;13:930087. doi: 10.3389/fimmu.2022.930087

Figure 5.

Figure 5

Comparison of the decision curves between the aGAPSS-IS score and aGAPSS in the training and the validation cohort. (A) For a threshold probability > 2%, application of the aGAPSS-IS score would add more net benefit to patients compared to the use of the aGAPSS in the training cohort. (B) For a threshold probability > 4%, the aGAPSS-IS score would provide more net benefit to APS patients than the aGAPSS in the validation cohort. aGAPSS adjusted Global Anti-Phospholipid Syndrome Score.